SYMDEKO

This brand name is authorized in Australia, Brazil, Canada, Israel, New Zealand.

Active ingredients

The drug SYMDEKO contains a combination of these active pharmaceutical ingredients (APIs):

1	Tezacaftor UNII 8RW88Y506K - TEZACAFTOR
2	Ivacaftor UNII 1Y740ILL1Z - IVACAFTOR
	Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance).
	Read more about Ivacaftor

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R07AX31		R Respiratory system → R07 Other respiratory system products → R07A Other respiratory system products → R07AX Other respiratory system products
Discover more medicines within R07AX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11833T, 11834W, 11854X, 11863J
BR	Câmara de Regulação do Mercado de Medicamentos	575020070000407
CA	Health Products and Food Branch	02478080
IL	מִשְׂרַד הַבְּרִיאוּת	8312, 8746
NZ	Medicines and Medical Devices Safety Authority	22304